ERAS · Erasca Inc
Price
Snapshot
50 fields · last close| Market Cap | $5.17B |
| P/E | — |
| Float | 284.4M |
| Beta | 0.71 |
| Volatility | 17.8% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 60 |
| Price | 15.17 |
| Change | +2.71% |
| Prev Close | 14.77 |
| Open | 15.41 |
| Day Low | 14.51 |
| Day High | 15.47 |
| Avg Vol | 5 |
| Avg $ Vol | $75.14M |
| 52W High | 24.28 |
| 52W Low | 1.67 |
| 52W Pos | 59.7% |
| From High | −37.52% |
| From Low | +808.38% |
| Max DD 1Y | −59.46% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −9.40% |
| SMA 50 | −15.00% |
| SMA 200 | +13.06% |
| RSI (14) | 32.0 |
| Vol 30D | 50.8% |
| Vol 90D | 66.9% |
| 1Y Range | 2–24 |
| Daily bars | 516 |
| Perf Week | −6.99% |
| Perf Month | −18.26% |
| Perf Quarter | +8.05% |
| Perf Half Y | −3.21% |
| Perf Year | +784.43% |
| Perf YTD | +322.56% |
| Prev Day | +2.71% |
| Clavix | C |
| Debt / Eq | 0.00 |
| Curr Ratio | 10.04 |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Mixed |
| Leverage | Low |
| Sector rank | 26 / 35 |
Clavix risk grade
regraded every trading dayERAS grades C, 60 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (38, fragile). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 26 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ERAS | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.71 | 0.51 |
| Volatilityannualized | 17.8% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −59.5% | — |
| Typical daily movemedian absolute daily change | 2.74% | — |
| Days beyond ±3%of the last 252 sessions | 11847% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ERAS | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.71 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ERAS | |
|---|---|
| 1 week | −7.0% |
| 1 month | −18.3% |
| Year to date | +322.6% |
| 1 year | +784.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ERAS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 27 Jul |
| Average score0 most bearish, 100 most bullish | 38 |
| Bullish · bearisharticles above 60 · below 40 | 10 · 20 |
| Directionarticles whose tone is improving vs worsening | 10 ↑ 20 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ERAS | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openLaw firm Johnson Fistel announced it is investigating potential claims against certain officers and directors of Erasca, Inc. on behalf of current long-term shareholders, alleging breaches of fiduciary duty. No lawsuit has been filed.
The FDA granted Fast Track Designation to Erasca's ERAS-0015, an oral pan-RAS molecular glue drug, for patients with metastatic pancreatic cancer that has spread. The designation followed July results from the AURORAS-1 Phase 1 trial showing a 57% response rate in second-line or later KRAS G12X pancreatic cancer patients on the 32 mg dose, with all responders still on treatment as of May 25.
Law firm Johnson Fistel announced it is investigating potential claims on behalf of long-term Erasca shareholders against certain company officers and directors for alleged breaches of fiduciary duty, meaning the legal duty to act in shareholders' best interests.
The law firm Johnson Fistel is investigating potential claims against certain officers and directors of Erasca on behalf of current long-term shareholders, over alleged breaches of fiduciary duty (the legal duty to act in shareholders' interests).
Bernstein Liebhard LLP, an investor rights law firm, announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. The article provides no further details on what conduct is being examined.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| PTCT | PTC Therapeutics Inc | B | $5.46B | 7.99 | 0.50 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $4.64B | — | 0.87 | Compare |
| CGON | CG Oncology Inc | B- | $6.61B | — | 0.21 | Compare |
| CELC | Celcuity Inc | C | $3.94B | — | 0.14 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.39B | — | 0.41 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.47B | 80.58 | 0.39 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.71B | 19.72 | 1.90 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.